Business
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
Net revenue increased to $28.2 million for Q2 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS® (voclosporin) for 2022
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":"\nNet revenue increased to $28.2 million for Q2 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS® (voclosporin) for 2022\n\nContinued increases in LUPKYNIS Patients on Treatment; Steady Conversion Rates and Payor Coverage\n\nEMA review of LUPKYNIS remains on track with decision expected by the end of Q3 2022\n\n$391.7 million of cash and investments as of June 30, 2022\n\nConference call to be hosted today at 8:30 a.m. ET\n\n VICTORIA, British Columbia--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the second quarter ended June 30, 2022. Amounts, unless specified otherwise, are expressed in U.S. dollars.\n\nSecond Quarter 2022 and Recent Highlights & Upcoming Milestones\n\n\nNet product revenues were $28.2 million for the quarter ended June 30, 2022, compared to $6.6 million for the same period ended June 30, 2021.\n\n\nAurinia added 409 patient start forms (PSFs) during the second quarter 2022, as compared to 415 in the second quarter of 2021. As of Friday, July 29, 2022, the Company recorded 981 total PSFs since January 1, 2022.\n\n\nPSF conversion rates after 90 days and confirmed patient access remain at peak levels since launch.\n\n\nThere were approximately 1,274 patients on LUPKYNIS therapy at June 30, 2022, compared with 1,071 at March 31, 2022.\n\n\nAt 6 months post-treatment-start, an average of approximately 70% of patients remain on treatment; and at 9 months, approximately 60% of patients are still on treatment.\n\n\n\n\nReceived positive CHMP opinion for LUPKYNIS® (voclosporin) for the treatment of adults with active lupus nephritis in Europe. Regulatory review of the European Medicines Agency (EMA) marketing authorization application (MAA) remains on track with a European Commission (EC) approval decision expected by the end of the third quarter of 2022.\n\n\nThe first presentations of final AURORA 2 continuation study data were presented at the following medical meetings:\n\n\n59th European Renal Association (ERA) Congress;\n\n\nthe European Congress of Rheumatology;\n\n\nthe European Alliance of Associations for Rheumatology (EULAR); and,\n\n\nSubmission of a manuscript with the full results is expected in the second half of 2022.\n\n\n\n\nRecruitment of patients and initiation of new sites into...